President, SIOPEN and SIOPEN AGM Institute Gustave ......Brauhaus Lemke am Alex Charité Berlin...
Transcript of President, SIOPEN and SIOPEN AGM Institute Gustave ......Brauhaus Lemke am Alex Charité Berlin...
-
20
Conference Chairs Prof. Dr. Angelika Eggert Chair, GPOH Neuroblastoma Study Group Charité University Medicine Berlin Campus Virchow Klinikum
Prof. Dr. Dominique Valteau-Couanet President, SIOPEN Institute Gustave Roussy Paris
Organization:
B. Kömür/Ch. Guirassy
GPOH-Office: G. Mechelk/L. Wünschel
Klinik für Pädiatrie m.S. Onkologie & Hämatologie
Charité, Campus Virchow Klinikum
Augustenburger Platz 1, 13353 Berlin
Fon: +49 30/450-566 132
Fax: +49 30/450-566 906
E-Mail: [email protected]
1st SIOPEN/GPOH Neuroblastoma Research Symposium
and SIOPEN AGM
October 25 - 27, 2017
Langenbeck Virchow Haus, Berlin, Germany
-
2
Dear Colleagues and Friends,
we are delighted to welcome you to the 1st International SIOPEN/GPOH Symposium
for Neuroblastoma Research & SIOPEN Annual General Meeting 2017. We are look-
ing forward to a historic meeting laying the official foundation for future joint clini-
cal trials of the two trial groups. We are very happy to welcome the SIOPEN commu-
nity for the first time in Berlin! This beautiful and historic city is not only the capital
of Germany, but it is also the birthplace of neuroblastoma first described by Ru-
dolph Virchow in 1864. For this reason, we decided to host the Welcome Reception
in the historic Virchow lecture hall including a tour of the Museum of Medical Histo-
ry with the Virchow collection on display. We are extremely grateful to the Program
Committee and the SIOPEN EC for their dedication, enthusiasm, and expert advice.
They have developed a truly integrative program that captures the breadth and
depth of neuroblastoma research and emphasizes the critical role of convergent
science in translating research for clinical benefit. Presentations will cover the latest
basic, translational and clinical neuroblastoma research including important topics
such as tumor evolution, liquid biopsies and new drugs. There are numerous oppor-
tunities for attendees to present their work, make fruitful connections, and engage
in dialogue with colleagues and thought leaders from around the world. From the
55 abstracts received, we were able to accommodate 11 abstracts as short oral
presentations throughout the scientific program. All abstracts will be displayed as
posters. We feel confident that you will leave the meeting with a renewed sense of
energy, inspiration, and focus on your neuroblastoma work.
We look forward to meeting you in person, and to discuss many interesting research
topics and clinical questions!
Sincerely yours,
Angelika Eggert, Chair, GPOH neuroblastoma trial group
Dominique Valteau-Couanet, President, SIOPEN trial group
19
Veranstalter und Organisator: GPOH e.V. und SIOPEN
Wissenschaftliche Leitung: Prof. Dr. Angelika Eggert
Prof. Dr. Dominique Valteau-Couanet
Tagungsdatum: 25.-27.10.2017
Tagungsort:
Langenbeck Virchow Haus Luisenstr. 58/59 10117 Berlin
Teilnahmegebühren: 60,- €
Anmeldung unter:
http://members.siopen.org/page-1778036
Zertifizierung für Ärzte (CME):
Die Zertifizierung der Veranstaltung ist bei der Ärztekammer beantragt.
Quellen für Bilder u. Grafiken:
Titelbild: https://de.fotolia.com/id/57185897
Brauhaus Lemke am Alex
Charité Berlin
Sponsor: EUSA Pharma, 17.000 € zzgl. USt.
http://members.siopen.org/EmailTracker/LinkTracker.ashx?linkAndRecipientCode=iNduHZlXiHmlpZEkqwLWo%2fV0fRu0d16J96yrUMsjBBRSZHR8IeL2YU5RdhpTd3NYpvYlWTG%2fdYaCRfwO6NLx5TD%2bGw%2fReoXwMKNUrDqf2cY%3dhttps://de.fotolia.com/id/57185897
-
18
Langenbeck Virchow Haus
Luisenstr. 58/59
10117 Berlin
X X
Langenbeck Virchow
Haus
Welcome Reception
3
1st SIOPEN/GPOH Neuroblastoma Research Symposium
Langenbeck Virchow Haus, Berlin, Germany
Wednesday, Oct 25th - Translational Neuroblastoma Research
(Lecture Hall)
09.00 h - 09.30 h Registration, Coffee and Poster Setup
09.30 h Welcome A. Eggert, Berlin/D. Valteau-Couanet, Paris
09.35 h - 10.50 h Molecular Risk Stratification
Chairs: K. de Preter, Ghent/F. Westermann, Heidelberg
09.35 h - 09.50 h
Molecular characterization of neuroblastoma for risk stratification and clinical
decision making
G. Schleiermacher, Paris
09.50 h - 10.05 h
Risk stratification of non-HR neuroblastoma according to gene expression
classification
C. Rosswog, Cologne
10.05 h - 10.20 h
Identification of ultra-HR patients using copy number alterations
K. de Preter, Ghent
10.20 h - 10.35 h
Identification of ultra-HR patients using gene expression profiling
M. Capasso, Napels
-
4
10.35 h - 10.50 h
Definition of risk groups according to telomere maintenance and RAS/p53 pathway mutations
S. Ackermann/M. Fischer, Cologne
10.50 h - 12.05 h Liquid Biopsies
Chairs: S. Burchill, Leeds/H. Deubzer, Berlin
10.50 h - 10.55 h
Introduction to Liquid Biopsies
S. Burchill, Leeds
10.55 h - 11.15 h Keynote Lecture
Measurement and role of ctDNA in diagnostics and monitoring of neuroblastoma
G. Schleiermacher, Paris
11.15 h - 11.30 h
cfDNA/ddPCR defined targets and blood metabolites in neuroblastoma
H. Deubzer, Berlin/M. Lodrini, Berlin
11.30 h - 11.45 h
Disease monitoring based on mRNA measurements in liquid biopsies
S. Burchill, Leeds
11.45 h - 11.55 h Free Paper
Prognostic value of residual tumor cells after induction chemotherapy in the bone marrow of stage M neuroblastoma patients and its relation to tumor genetics: A SIOPEN Biology and Bone Marrow study
S. Fiedler, Vienna
17
Thursday, Oct 26th
20.00 h Dinner: Berlin Beer Brewery: Beer Tasting and Typical Berlin Dinner
(Schnitzel, Currywurst…), Life Music + Dance
Ticket: 50,- € (sold out)
Brauhaus Lemke am Alex Karl-Liebknecht-Str. 13 10178 Berlin
Referents and Chairs:
S. Ackermann, Cologne
P. Ambros, Vienna
J. Anderson, London
M. Arsenian, Stockholm
S. Ash, Tel Aviv
G. Barone, London
K. Beiske, Oslo
C. Beltinger, Ulm
T. Boterberg, Ghent
S. Burchill, Leeds
A. Cañete, Valencia
M. Capasso, Napels
R. Castellani, Milan
L. Chen, Newcastle
L. Chesler, London
O. Cormac, Dublin
K. de Preter, Ghent
H. Deubzer, Berlin
S. Durand, Paris
C. Dyberg, Stockholm
A. Eggert, Berlin
J. Park, Seattle
A. Pearson, London
U. Poetschger, Vienna
S. Sarnacki, Paris
G. Schleiermacher, Paris
J. Schulte, Berlin
V. Segura, Valencia
J. Shohet, Houston
S. Sorrentino, Genoa
F. Speleman, Ghent
S. Taschner-Mandl, Vienna
K. Toews, Berlin
T. Trahair, Sydney
D. Tweddle, Newcastle
D. Valteau-Couanet, Paris
L. van Zogchel, Utrecht
R. Versteeg, Amsterdam
F. Westermann, Heidelberg
M. Eilers, Würzburg
M. Fischer, Cologne
M. Gaze, London
R. George, Boston
M. Halasz, Dublin
R. Haupt, Genoa
A. Henssen, Berlin
P. Hundsdörfer, Berlin
I. Janoueix, Paris
P. Kogner, Stockholm
A. Künkele, Berlin
R. Ladenstein, Vienna
P. Lang, Tübingen
H. Lode, Greifswald
M. Lodrini, Berlin
G. Marshall, Sydney
J. Molenaar, Utrecht
L. Moreno, Madrid
M. Morini, Genoa
-
16
Friday, Oct 27th SIOPEN AGM (Lecture Hall)
08.30 h—15.45 h
08.30 h 10.00 h SIOPEN AGM - Agenda
circulated among the
Members
D. Valteau-Couanet
10.00 h 10.30 h Coffee Break
10.30 h 13.00 h High Risk Session
10.30 h 11.30 h COG HR Strategy J. Park
11.30 h 13.00 h HR-NBL-2 D. Valteau-Couanet
13.00 h 14.00 h Lunch
14.00 h 15.30 h Relapse session
14.00 h 14.45 h New drug development L. Moreno, C. Owens, A. Eggert
14.45 h 15.30 h Relapse strategy A. Eggert, H. Lode, L. Moreno
15.30 h 15.45 h Break
15.30 h 15.45 h Conclusions D. Valteau-Couanet, A. Eggert
5
11.55 h - 12.05 h Free Paper
Liquid biopsies reveal exosomal miRNA modulation in high-risk neuroblastoma
patients after induction therapy
M. Morini, Genoa
12.05 h- 13.00 h Tumor Heterogeneity + Tumor Microenvironment
Chair: A. Eggert, Berlin/P. Ambros, Vienna
12.05 h - 12.10 h Introduction
A. Eggert, Berlin
12.10 h - 12.30 h Keynote lecture
Tumor heterogeneity in neuroblastoma
P. Ambros, Vienna
12.30 h - 12.45 h
Defining molecular heterogeneity by ssRNA-seq
J. Shohet, Houston
12.45 h - 13.00 h
Inflammation in the neuroblastoma microenvironment
P. Kogner, Stockholm
13.00 h - 13.45 h Lunch
13.45 h - 15.20 h Targeting MYCN
Chairs: M. Eilers, Würzburg/M. Arsenian, Stockholm
13.45 h - 14.10 h Keynote Lecture
Role of MYCN in Neuroblastoma
M. Arsenian, Stockholm
-
6
14.10 h - 14.25 h
Targeting MYCN with Aurora kinase inhibitors
M. Eilers, Würzburg
14.25 h - 14.40 h
Inhibition of MycN protein stability
G. Marshall, Sydney
14.40 h - 14.55 h
Targeting MYCN with a CDK9/2 inhibitor
L. Chesler, London
14.55 h - 15.10 h Free Paper
Targeting MYCN with metronomic therapy inducing senescence in neuroblastoma
S. Taschner-Mandl, Vienna
15.10 h - 15.20 h Free Paper
Spliceosomal components as potential therapeutic targets for the therapy of
children with high-risk MYCN-amplified neuroblastoma
M. Halasz, Dublin
15.20 h - 16.00 h Coffee Break + Poster Viewing
16.00 h - 17.30 h New Immunotherapy Approaches
Chairs: H. Lode, Greifswald/A. Künkele, Berlin
16.00 h - 16.25 h Keynote lecture
CD171-specific CAR-T cells: experience from the Seattle Children’s hospital
J. Park, Seattle
16.25 h - 16.50 h Keynote lecture
GD2-specific CAR-T cells: experience from the UCL Great Ormond Street
J. Anderson, UCL Great Ormond Street Institute of Child Health, London
15
Thursday, Oct 26th
14.00 h – 19.00 h SIOPEN AGM (Lecture Hall)
14.00 h 15.45 h Low and Intermediate Risk Session Chairman:
D. Valteau- Couanet
Speakers
14.00 h 15.30 h LINES (60’)
Opsoclonus Myoclonus - OMS (15’)
NB-SCI Working Group (15')
A. Cañete
G. Schleiermacher
R. Haupt
15.30 h 15.45 h Coffee break
15.45 h 18.00 h High Risk Session Chairman:
D. Valteau- Couanet
Speakers
HR-NBL-1 (60’)
LTI Studies (30’)
VERITAS (5’)
Pilot studies CT+AntiGD2 (30’)
Bioportal (10’)
R. Ladenstein, U. Poetschger
H. Lode
D. Valteau-Couanet
H. Lode
G. Schleiermacher
18.00 h 19.00 h Bioportal (closed) G. Schleiermacher, R. Laden-
stein
-
14
Thursday, Oct 26th
13.00 h - 14.00 h
Lunch Symposium: Dinutuximab Beta (sponsored by EUSAPHARMA)
13.00 h – 13.15 h
H. Lode, Greifswald:
Management and treatment tolerance of Dinutuximab Beta longterm infusion
13.15 h – 13.30 h
R. Ladenstein, Vienna:
What are the key benefits of Dinutuximab Beta in the first line maintenance setting?
13.30 – 13.45
P. Hundsdörfer, Berlin:
Role of IL2 in treatment tolerance of Dinutuximab Beta
13.45 – 14.00 h
Discussion and questions from the audience
7
16.50 h - 17.05 h
Towards Biomarkers for immunotherapy with dinutuximab
H. Lode, Greifswald
17.05 h - 17.15 h Free Paper
Haploidentical stem cell transplantation and subsequent immunotherapy with
antiGD2 antibody for patients with relapsed metastatic neuroblastoma
P. Lang, Tübingen
17.15 h - 17.25 h Free Paper
Evaluating the role of PD-1/PD-L1 and the influence of PD-1 inhibition on CAR-T-cell therapy efficacy in neuroblastoma
K. Toews, Berlin
17.25 h - 19.00 h New Drug Targets/Drug Development/Early Clinical Trials
Chairs: L. Moreno, Madrid/O. Cormac, Dublin
17.25 h - 17.50 h Keynote Lecture
Drug development in neuroblastoma - can we be faster?
A. Pearson, London
17.50 h - 18.05 h
New methodology for early clinical trials
L. Moreno, Madrid
18.05 h – 18.20 h
Drug targets in relapsed neuroblastoma identified on the INFORM platform
F. Westermann, Heidelberg
18.20 h - 18.35 h
Integration of targeted therapy with immunotherapy
G. Barone, London
-
8
18.35 h - 18.45 h Free Paper
Rho-associated kinase is a therapeutic target in neuroblastoma
C. Dyberg, Stockholm
18.45 h - 18.55 h Free Paper
In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone
and in combination with temozolomide in TP53 wild-type orthotopic models of
neuroblastoma
L. Chen, Newcastle
19.00 h - 20.00 h Poster viewing with drinks
13
Thursday, Oct 26th
SIOPEN 2017 Annual General Meeting
08.00 h—09.00 h EC & AB Meeting (closed) - D. Valteau-Couanet
09.00 h – 13.00 h SIOPEN: Specialty Committees/Working Groups/Parallel
Sessions - By invitation only
09.00 h 13.00 h LINES & Neonates A. Cañete Room Rudolf Virchow
2. floor
09.00 h 13.00 h NB-SCI Workshop S. Ash/R. Haupt/
S. Sorrentino/
T. Trahair
Room Werner Körte
1. floor
09.00 h 11.30 h Radiotherapy T. Boterberg Room Bernhard von
Langenbeck
1. floor
09.00 h 11.30 h Surgery S. Sarnacki Room Emil von Behring
4. floor
09.00 h 11.30 h Molecular Monitor-
ing & Biology Joint
Meeting
S. Burchill/
P. Ambros/
G. Schleiermacher
Room Robert Koch
5. floor
11.30 h 12.30 h Radiotherapy &
Surgery Joint
Meeting
T. Boterberg/
S. Sarnacki
Room Bernhard von
Langenbeck
1. floor
11.30 h 12.30 h Nuclear Medicine R. Castellani Room Emil von Behring
4. floor
11.30 h 13.00 h Molecular Monitor-
ing
S. Burchill/
K. Beiske
Room Robert Koch
5. floor
12.30 h 13.00 h VERITAS joint
meeting with radio-
therapy
D. Valteau-
Couanet/M. Gaze
Room Bernhard von
Langenbeck
1. floor
-
12
12.20 h - 12.35 h
ALK inhibitor combinations & clinical aspects
D. Tweddle, Newcastle
12.35 h - 12.50 h
Heterogeneity and dynamics of ALK mutations
S. Durand, Paris
12.50 h - 13.00 h Free Paper
Circulating tumor DNA for disease monitoring in neuroblastoma
L. van Zogchel, Utrecht
9
Berliner Medizinhistorisches Museum der Charité Campus Charité Mitte Charitéplatz 1 10117 Berlin
20.00 h Welcome Reception - Historical Virchow Lecture Hall, Charité Mitte
with Guided Tour: Museum of Medical History
Prior Registration needed due to limited space!!
-
10
Thursday, Oct 26th Basic/Translational Research (Plenary Hall)
Clinical Research/SIOPEN AGM
08.00 h - 09.00 h EC & AB SIOPEN Meeting (closed) - D. Valteau-Couanet, Paris
08.00 h - 09.00 h Registration open
08.30 h - 10.00 h Neuroblastoma Pathogenesis
Chairs: R. Versteeg, Amsterdam/F. Speleman, Ghent
08.30 h - 09.00 h Keynote Lecture
The split personality of neuroblastoma
R. Versteeg, Amsterdam
09.00 h - 09.15 h
Deciphering super-enhancer landscape, transcriptional circuitries and cell identity in neuroblastoma
I. Janoueix, Paris
09.15 h - 09.30 h
Vulnerabilities of neuroblastoma defined by core transcriptionally regulatory
circuitries
F. Westermann, Heidelberg
09.30 h - 09.45 h
Copy number driven dependency genes implicated in core regulatory circuits and cellular states in neuroblastoma
F. Speleman, Ghent
09.45 h - 09.55 h Free Paper
Synthetic lethal targeting of PGBD5-induced DNA repair dependency in
neuroblastoma
A. Henssen, Berlin
11
09.55 h - 10.05 h Free Paper
Metabolome of childhood neuroblastoma: a pilot model
V. Segura, Valencia
10.05 h - 11.00 h New Preclinical Models: PDX, GEMM, zebrafish
Chairs: L. Chesler, London/C. Beltinger, Ulm)
10.05 h - 10.30 h Keynote Lecture
Neuroblastoma mouse models
L. Chesler, London
10.30 h - 10.45 h
Imaging studies of neuroblastoma GEMM and PDX models
C. Beltinger, Ulm
10.45 h - 11.00 h
Zebrafish neuroblastoma modeling: from the tank to the bedside and back
F. Speleman, Ghent
11.00 h - 11.30 h Coffee Break
11.30 h - 13.00 h Targeting RAS/MAPK & ALK
Chairs: J. Schulte, Berlin/R. George, Boston
11.30 h - 11.55 h Keynote Lecture
Targeting RAS/MAPK
J. Molenaar, Utrecht
11.55 h - 12.20 h Keynote Lecture
Targeting ALK
R. George, Boston